Addressing the EMEA Cold Chain Challenge for Cell and Gene Therapies: Cryoport Systems Featured in Labiotech.eu 

 As the EMEA region continues to emerge as a major player in the development of cell and gene therapies (CGTs), the complexity of cold chain logistics has become both a defining challenge and an area where Cryoport Systems leads with innovation and experience. 

In a recent Labiotech.eu article, our own Florent Belon, Managing Director for Cryoport Systems in France, discusses how regulatory diversity, infrastructure gaps, and extreme climate variation across Europe, the Middle East, and Africa (EMEA) are intensifying the need for customized, compliant cold chain solutions. 

“One main challenge we’re facing is the diverse regulation among countries within the EU on top of GMP Regulation,” explains Belon. “So when you add the Middle East and Africa, then you have numerous regulations that vary significantly.” 

The article explores how Cryoport Systems supports the growing decentralization of clinical trials by deploying regionally integrated supply chain hubs, providing temperature-controlled shipping and storage, and investing in AI-powered logistics, blockchain traceability, and sustainable infrastructure. Our reusable, sensor-equipped packaging and near real-time data platforms help safeguard patient-critical materials while reducing environmental impact. 

Florent also shares insights on how Cryoport Systems is building the future of cold chain through strategic partnerships and workforce innovation, including our role in the Campus Biotech Digital consortium with Sanofi and Servier to develop immersive VR training for biologics handling. 

From collaborating on ultra-cold shipping systems with Sarepta Therapeutics to advancing smart sustainability practices across our European sites, Cryoport Systems continues to push the boundaries of what’s possible in CGT logistics and supply chain processes. 

“We’re not just a logistics company,” says Belon. “We’re a science-led organisation that’s deeply embedded in the therapeutic journey.” 

Read the full article here:
Cracking the code: Delivering biotherapeutics successfully across EMEA